The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

Mon, 10th Jan 2022 11:29

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Tintra PLC, nearly triples to 155.00 pence, 12-month range 29.00p-155.00p. Shares in banking technology company hit 12-month high having raised a total of USD3 million from two share subscriptions priced at a significant premium to its current share price. Two investors have committed to subscriptions of USD1 million and USD2 million, priced at 504.00p per new share. This Windsor, Berkshire-based firm is building banking and infrastructure technology systems.

----------

Chariot Ltd, up 43% at 10.65p, 12-month range 5.00p-11.95p. Shares in the Africa-focused transitional energy company hit 12-month high as it makes significant gas discovery at its Anchois-2 well on the Anchois gas project. Says the well within the Lixus licence, offshore Morocco, was "safely and efficiently drilled", and it has undertaken a "comprehensive evaluation". Preliminary interpretation of the data confirmed the presence of "significant gas accumulations" in the appraisal and exploration objectives of the well.

----------

Tortilla Mexican Grill PLC, up 3.5% at 190.74p, up 5.0% from October's 181p initial public offering price. The fast-casual Mexican restaurant chain says it has put in a "very strong" trading performance since listing in London in October, shaking off Omicron restrictions. As a result, annual revenue and profit will be "materially ahead" of its expectations.

----------

AIM - LOSERS

----------

Avacta Group PLC, down 27% at 84.67p, 12-month range 80.16p-291.80p. Shares in cancer-focused immunotherapies developer hit 12-month low after halting the sales of its AffiDX antigen test due to its lower sensitivity to detecting the Omicron variant of Covid-19. Avacta says cause for the lower sensitivity of the test is the antibody with which the company Affimer is paired. As such, Avacta has paused sales of the antigen test, as it works to replace the antibody in the product to improve its performance.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Related Shares

More News
1 May 2024 11:53

IN BRIEF: Avacta picks Christina Coughlin to replace long-serving CEO

Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to ...

30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

23 Apr 2024 14:26

UK earnings, trading statements calendar - next 7 days

22 Apr 2024 17:51

TRADING UPDATES: First Tin updates Tellerhauser estimates

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

21 Mar 2024 13:10

Avacta reaches milestone in AVA6000 dose escalation

(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thur...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.